Eliem Therapeutics Shares Owned By Insiders vs. Book Value Per Share
| ELYMDelisted Stock | USD 3.04 0.19 5.88% |
For Eliem Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eliem Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eliem Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eliem Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eliem Therapeutics over time as well as its relative position and ranking within its peers.
Eliem |
Eliem Therapeutics Book Value Per Share vs. Shares Owned By Insiders Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Eliem Therapeutics's current stock value. Our valuation model uses many indicators to compare Eliem Therapeutics value to that of its competitors to determine the firm's financial worth. Eliem Therapeutics is rated # 5 in shares owned by insiders category among its peers. It also is rated # 5 in book value per share category among its peers creating about 0.32 of Book Value Per Share per Shares Owned By Insiders. The ratio of Shares Owned By Insiders to Book Value Per Share for Eliem Therapeutics is roughly 3.12 . At this time, Eliem Therapeutics' Book Value Per Share is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Eliem Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Eliem Book Value Per Share vs. Shares Owned By Insiders
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Eliem Therapeutics |
| = | 10.38 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Eliem Therapeutics |
| = | 3.33 X |
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
Eliem Book Value Per Share Comparison
Eliem Therapeutics is currently under evaluation in book value per share category among its peers.
Eliem Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Eliem Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eliem Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Eliem Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Eliem Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2 K | -2.1 K | |
| Operating Income | -21.5 M | -22.5 M | |
| Net Loss | -39.2 M | -41.2 M | |
| Income Before Tax | -35.1 M | -36.9 M | |
| Total Other Income Expense Net | -13.7 M | -13 M | |
| Net Loss | -40.7 M | -42.8 M | |
| Net Loss | -35.1 M | -36.9 M | |
| Income Tax Expense | -21.5 K | -22.5 K | |
| Non Operating Income Net Other | -125.3 K | -131.6 K | |
| Net Interest Income | 4.6 M | 3.3 M | |
| Interest Income | 4.6 M | 3.3 M | |
| Change To Netincome | 8.5 M | 6.3 M | |
| Net Loss | (1.30) | (1.37) | |
| Income Quality | 0.59 | 0.79 | |
| Net Income Per E B T | 0.90 | 0.57 |
Eliem Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Eliem Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eliem Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eliem Therapeutics' important profitability drivers and their relationship over time.
Use Eliem Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eliem Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will appreciate offsetting losses from the drop in the long position's value.Eliem Therapeutics Pair Trading
Eliem Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Eliem Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eliem Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eliem Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eliem Therapeutics to buy it.
The correlation of Eliem Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eliem Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eliem Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eliem Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Eliem Therapeutics position
In addition to having Eliem Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Restaraunts Hotels Motels Thematic Idea Now
Restaraunts Hotels Motels
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Restaraunts Hotels Motels theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Restaraunts Hotels Motels Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |